ClinicalTrials.gg
RecruitingNCT05199194DIRECT-TNKUpdated Apr 4, 2025

Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke

A Phase 3 interventional study of Tenecteplase and Placebo in Stroke, Ischemic and Stroke, Acute, sponsored by Hospital Moinhos de Vento. Recruiting at 13 sites in Brazil. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Hospital Moinhos de Vento · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
32nd of 59
398 · median 466
Started
2022
with 6 others
Phase 3
37 of 59
23 open now
Primary completion
2026-07
later than 3 of 31 live
Registered
19th of 59
by date
Lead sponsor
2 of 59
Hospital Moinhos de Vento

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 32nd largest by planned enrollment, is one of 7 that started in 2022, is one of 37 in phase 3, reaches primary completion later than 3 of the 31 other live ones, and was the 19th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

A phase III randomized, multi-center, double-blinded, placebo-controlled clinical trial that will examine two strategies for the treatment of acute ischemic stroke associated with a large vessel anterior occlusion within 4.5 hours from symptoms onset: direct endovascular treatment vs. endovascular treatment preceded by intravenous tenecteplase.

Read the detailed description

Randomized, prospective, multicenter, double-blinded, placebo-controlled clinical trial with adaptive desing. Randomization will be 1:1 according to reperfusion treatment modalities: (A) (with placebo TNK) direct mechanical thrombectomy vs. (B) Intravenous thrombolysis with TNK (0.25 mg/kg) plus mechanical thrombectomy. Randomization will be done by a minimization process using age, National Institute of Health Stroke Scale (NIHSS) score, and site of the occluded artery. For the primary outcome, the subjects will be followed up within 90 days after randomization. The primary outcome will be the ordinal distribution from the modified Rankin scale score (mRS).

Subjects presenting acute ischemic stroke within 4.5 hours of the onset of symptoms attributable to an occlusion of intracranial internal carotid or of the proximal middle cerebral artery (MCA, M1- or M2-segment) with or without tandem occlusion of cervical internal carotid confirmed by vascular neuroimaging. Subjects should be eligible for IV thrombolysis. In the sample size calculation, a difference in treatment effect between the groups (achievement of mRS 0 to 2 at 90 days) of 10.6% was considered, with 33.8% in the intervention group (TNK + thrombectomy) and 23.2% in the control group (placebo + thrombectomy), using a unilateral alpha of 0.025, with a power of 80%, resulting in a sample size of 358 participants. Considering a loss ratio of 10%, a sample size of 398 participants is estimated (199 in each treatment arm). An interim analysis is planned to be executed with 50% and 75% of the total sample. It allows the trial to be terminated in the case of efficacy or futility, in addition to enabling adaptive designed based on conditional probability of a positive result.

03

Conditions studied

  • Stroke, Ischemic
  • Stroke, Acute

Keywords

  • Tenecteplase
  • TNK
  • MT
  • Mechanical Thrombectomy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute ischemic stroke where a patient is eligible for IV thrombolytic treatment within 4.5 hours of stroke onset.
  • No significant pre-stroke functional disability (mRS ≤ 1)
  • Baseline NIHSS scores obtained before randomization must be equal to or higher than 6 points
  • Age equal ≥ 18 and =\< 85 years
  • Occlusion (TICI 0-1) of the ICA or proximal MCA segments (M1 or M2) suitable for endovascular treatment, as evidenced by CTA, MRA, or angiogram, with or without concomitant cervical carotid stenosis or occlusion.
  • Patient randomized within 4.5 hours of symptom onset. Symptoms onset is defined as the point in time the patient was last seen well (at baseline). Treatment start is defined as groin puncture, max 90 minutes after randomization.

    • Patients who have woken up with the symptoms and who have a mismatch FLAIR-DWI according to the WAKE-UP Trial will be considered as having a time window of \<4.5h.
  • obtained from the patient or acceptable patient surrogate.

Exclusion criteria

Exclusion Criteria:

  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with > 1.7 or direct oral anticoagulants such as thrombin antagonists (ex: dabigatran) or X factor (ex: rivaroxaban, apixaban, edoxaban) at the least 48 hours.
  • Baseline count \< 100.000/μL
  • Baseline blood glucose of \< 50mg/dL or > 400mg/dl
  • Severe, sustained hypertension (SBP > 185 mm Hg or DBP > 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.
  • Patients in coma (NIHSS item of consciousness >1) (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).
  • Seizures at stroke onset which would preclude obtaining a baseline NIHSS
  • Serious, advanced, or terminal illness with anticipated of less than one year.
  • History of life-threatening allergy (more than rash) to contrast medium.
  • Subjects who has received IV t-PA treatment before the randomization.
  • Renal failure with serum creatinine ≥ 3 mg/dl
  • Woman of who is known to be pregnant or who has a positive pregnancy test on admission.
  • Subject participating in a study involving an drug or device that would impact this study.
  • Cerebral vasculitis, endocarditis or subarachnoid hemorrhage.
  • Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.
  • Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).
  • Hypodensity on CT more than one third of MCA territory or hypersignal in more than one third of MCA territory on MR-DWI.
  • ASPECTS score \< 6 (no contrast at least 5 mm cut imaging on CT) or on MR-DWI sequence.
  • CT or MR evidence of hemorrhage (the presence of \< 5 GRE, SWI, SWAN microbleeds is allowed).
  • Significant mass effect with midline shift.
  • Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment.
  • Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
  • Evidence of intracranial tumor (except small meningioma).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    Mechanical Thrombectomy preceded by TNK

    Subjects assigned to this arm will receive an intravenous bolus of tenecteplase (0.25mg/kg) before the mechanical thrombectomy.

    Drug: Tenecteplase

  • Placebo comparator
    Mechanical Thrombectomy preceded by Placebo

    Subjects assigned to this arm will receive an intravenous bolus of matching placebo (with the same volume of infusion as of 0.25mg/kg of tenecteplase) before the mechanical thrombectomy.

    Drug: Placebo

Interventions

  • Intravenous thrombolysis with tenecteplase 0.25mg/kg

    Also known as: TNK

  • DrugPlacebo

    Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg

06

What researchers measure

Primary outcomes

  1. Distribution of the modified Rankin Scale scores at 90 days

    Distribution of the modified Rankin Scale scores (shift analysis).

    Time frame: 90 days

Secondary outcomes

  1. Functional independence defined as modified Rankin Score ≤ 2

    Functional independence defined as modified Rankin Score ≤ 2

    Time frame: 90 days

  2. Infarct volume evaluated on CT at 24 hours (-2/+12 hours).

    Infarct volume evaluated on CT at 24 hours (-2/+12 hours).

    Time frame: 24 hours

  3. Dramatic early favorable response as determined by a National Institute of Health Stroke Scale (NIHSS) of 0-2 or NIHSS improvement ≥ 10 points at 24 (-2/+12 hours) hours.

    Dramatic early favorable response as determined by a National Institute of Health Stroke Scale of 0-2 or NIHSS improvement ≥ 10 points at 24 (-2/+12 hours) hours.

    Time frame: 24 hours

  4. Cost-effectiveness analysis of endovascular therapy alone vs. endovascular therapy associated with tenecteplase

    Cost-effectiveness analysis of endovascular therapy alone vs. endovascular therapy associated with tenecteplase

    Time frame: 12 months

  5. Quality of life analysis as measured by EuroQol/EQ5D at 3 month, 6 months and one year among the groups

    Quality of life analysis as measured by EuroQol/EQ5D at 3 month, 6 months and one year among the groups

    Time frame: 3 months, 6 months and 12 months

  6. Score distribution of mRS at 90 days (shift analysis) in patients presenting M2-CMA occlusion

    Score distribution of mRS at 90 days (shift analysis) in patients presenting M2-CMA occlusion

    Time frame: 90 days

  7. Vessel recanalization evaluated by CT angiography or MRA at 24 hours in both treatment groups

    Vessel recanalization evaluated by CT angiography or MRA at 24 hours in both treatment groups

    Time frame: 24 hours

  8. Vessel recanalization post procedure in the endovascular arm assessed by TIMI grades and adjudicated by a central core-lab. Successful recanalization is defined as TICI (Thrombolysis in Cerebral Infarction) 2b or 3 on the post-procedure angiogram.

    Vessel recanalization post procedure in the endovascular arm assessed by TIMI grades and adjudicated by a central core-lab. Successful recanalization is defined as TICI (Thrombolysis in Cerebral Infarction) 2b or 3 on the post-procedure angiogram.

    Time frame: Immediately Post-procedure

Other outcomes

  1. Mortality at 90 days

    Mortality at 90 days

    Time frame: 90 days

  2. Mortality related to stroke and complications at 90 days

    Mortality related to stroke and complications at 90 days

    Time frame: 90 days

  3. Clinically significant ICH rates at 24 (-2/+12) hours.

    All intracerebral hemorrhages will be classified by a central core-lab using the ECASS criteria. Symptomatic ICH will be defined as per the SITS-MOST definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans. The incidence of any asymptomatic hemorrhage measured at 24 (-2/+12) hours will also be compared.

    Time frame: 24 hours

  4. Procedural related complications

    arterial perforation, arterial dissection, and embolization in a previously uninvolved vascular territory

    Time frame: 7 days

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jul 2026, 50 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 50 months is above that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Jan 20, 2022
StartActual
May 27, 2022
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05199194
Lead sponsor
Hospital Moinhos de Vento
Collaborators
Ministry of Health, Brazil, Boehringer Ingelheim, Medtronic
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
May 27, 2022
Primary completion
Jul 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Apr 4, 2025

Study contacts

Octavio M Pontes-Neto, MD, PhD
Contact
opontesneto@fmrp.usp.br
+551636053779
Leonardo A Carbonera, MD, MSc
Contact
leonardo.carbonera@hmv.org.br
+555135378195
Octavio M Pontes-Neto, MD, PhD
principal investigator · Hospital de Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo
Sheila CO Martins, MD, PhD
principal investigator · Hospital Moinhos de Vento
Raul G Nogueira, MD
principal investigator · University of Pittsburgh Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion